Used in treatment of post-Covid infection
Ambalal Sarabhai Enterprises (ASE) announced that Synbiotics, a subsidiary of ASE is the only manufacturer of the Active Pharmaceutical Ingredient (API) Amphotericin B in India and looking at the current outbreak of MUCORMYCOSIS and expected requirement, Synbiotics has ramped up the manufacturing capacity to meet the requirement of this most effective anti-fungal Antibiotic in the post Covid crisis.Synbiotics has the State of the Art fermentation plant for the manufacturing of the API Amphotericin B.
India is witnessing an outbreak of MUCORMYCOSIS - a very fast spreading fungal infection especially for post-COVID infection and recovery because of low immune system in the patients. The most recommended treatment for this infection is Amphotericin B injection.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
